ArticleAmerican journal of translational research2026
Clinical value of targeted arterial infusion of ginkgo biloba extract combined with urokinase in thromboangiitis obliterans.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy and safety of targeted artery infusion of Ginkgo biloba extract (GBE) combined with urokinase (URK) for treatment of thromboangiitis obliterans (TAO), and to provide a reference for the optimized treatment of TAO.
methodsA total of 108 male TAO patients (December 2021-December 2023) were retrospectively enrolled and divided into a GBE group (54 cases, single GBE infusion) and a GBE-URK group (54 cases, GBE+URK infusion) after propensity score matching. Both groups received 72-hour continuous infusion, followed by standardized adjuvant therapy and 12-month follow-up. Key indices (pain, hemodynamics, inflammation) and safety/recurrence were compared.
resultsAt 90 days, the GBE-URK group had lower FPS-R scores (1.89±0.84 vs 2.74±0.48, P<0.001), intermittent claudication scores (1.00±0.55 vs 1.69±0.61, P<0.001), and higher pain relief rate (94.44% vs 70.37%, P = 0.001). At 30 days, it had a higher ABI (1.14±0.22 vs 0.82±0.16, P<0.001), TBI (1.09±0.30 vs 0.76±0.26, P<0.001) and lower TNF-α (29.99±4.27 vs 39.99±5.14 pg/mL, P<0.001), ET-1 (189.85±19.20 vs 268.17±37.44 pg/mL, P<0.001). Adverse reaction rates were 7.41% vs 14.81% (P = 0.221); 12-month recurrence-free survival was higher in GBE-URK group (Log-rank P = 0.009). This was confirmed to be an independent factor by multivariable regression (P<0.05).
conclusionsGBE-URK infusion improves pain, hemodynamics, and long-term prognosis in TAO, providing a safe, minimally invasive strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.